de Koning, Heleen D <br/><br/>
Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.  [electronic resource] 

 -  The Journal of allergy and clinical immunology  Dec 2011 
 - 1352-4 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment 
<br/><br/><label>ISSN: </label>1097-6825 
<br/><br/><label>Standard No.: </label>10.1016/j.jaci.2011.05.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antirheumatic Agents--therapeutic use<br/>Autoimmune Diseases--drug therapy<br/>Female<br/>Hereditary Autoinflammatory Diseases--drug therapy<br/>Humans<br/>Interleukin 1 Receptor Antagonist Protein--therapeutic use<br/>Interleukin-1--antagonists & inhibitors<br/>Interleukin-1beta--metabolism<br/>Schnitzler Syndrome--drug therapy<br/>Tumor Necrosis Factor-alpha--metabolism